TransMedics Group Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $56.56
- Today's High:
- $59.62
- Open Price:
- $58.87
- 52W Low:
- $38.86
- 52W High:
- $99.63
- Prev. Close:
- $59.53
- Volume:
- 848563
Company Statistics
- Market Cap.:
- $2.26 billion
- Book Value:
- 4.457
- Revenue TTM:
- $151.08 million
- Operating Margin TTM:
- -10.14%
- Gross Profit TTM:
- $65.27 million
- Profit Margin:
- -11.77%
- Return on Assets TTM:
- -2.37%
- Return on Equity TTM:
- -18.13%
Company Profile
TransMedics Group Inc had its IPO on 2019-05-02 under the ticker symbol TMDX.
The company operates in the Healthcare sector and Medical Devices industry. TransMedics Group Inc has a staff strength of 212 employees.
Stock update
Shares of TransMedics Group Inc opened at $58.87 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $56.56 - $59.62, and closed at $57.68.
This is a -3.11% slip from the previous day's closing price.
A total volume of 848,563 shares were traded at the close of the day’s session.
In the last one week, shares of TransMedics Group Inc have slipped by -16.55%.
TransMedics Group Inc's Key Ratios
TransMedics Group Inc has a market cap of $2.26 billion, indicating a price to book ratio of 9.9924 and a price to sales ratio of 26.4418.
In the last 12-months TransMedics Group Inc’s revenue was $151.08 million with a gross profit of $65.27 million and an EBITDA of $-10463000. The EBITDA ratio measures TransMedics Group Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, TransMedics Group Inc’s operating margin was -10.14% while its return on assets stood at -2.37% with a return of equity of -18.13%.
In Q2, TransMedics Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 155.7%.
TransMedics Group Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TransMedics Group Inc’s profitability.
TransMedics Group Inc stock is trading at a EV to sales ratio of 24.256 and a EV to EBITDA ratio of -48.6707. Its price to sales ratio in the trailing 12-months stood at 26.4418.
TransMedics Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $690.36 million
- Total Liabilities
- $32.02 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.38 million
- Dividend Payout Ratio
- 0%
TransMedics Group Inc ended 2024 with $690.36 million in total assets and $0 in total liabilities. Its intangible assets were valued at $690.36 million while shareholder equity stood at $145.21 million.
TransMedics Group Inc ended 2024 with $0 in deferred long-term liabilities, $32.02 million in other current liabilities, 627747000.00 in common stock, $-482314000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $582.21 million and cash and short-term investments were $582.21 million. The company’s total short-term debt was $1,880,000 while long-term debt stood at $504.67 million.
TransMedics Group Inc’s total current assets stands at $662.66 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $47.52 million compared to accounts payable of $7.03 million and inventory worth $30.55 million.
In 2024, TransMedics Group Inc's operating cash flow was $0 while its capital expenditure stood at $1.38 million.
Comparatively, TransMedics Group Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $57.68
- 52-Week High
- $99.63
- 52-Week Low
- $38.86
- Analyst Target Price
- $95.5
TransMedics Group Inc stock is currently trading at $57.68 per share. It touched a 52-week high of $99.63 and a 52-week low of $99.63. Analysts tracking the stock have a 12-month average target price of $95.5.
Its 50-day moving average was $75.86 and 200-day moving average was $71.92 The short ratio stood at 4.43 indicating a short percent outstanding of 0%.
Around 355.2% of the company’s stock are held by insiders while 9447.4% are held by institutions.
Frequently Asked Questions About TransMedics Group Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.